Bayhill Therapeutics

San Mateo, CA

Bayhill is a biopharmaceutical company focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company is developing DNA-antigen vaccines and oligonucleotides that are specifically designed to promote immune intolerance. Bayhill's lead compound, an antigen-specific immunotherapy aimed at treating multiple sclerosis, has completed a Phase 2 trial. The company also has a Type 1 diabetes program in a Phase 1/2 trial.